As Director, AI Strategy for the INDIGO AI Innovation Lab, you will serve as the enterprise thought partner and catalyst for responsible, high‑value AI adoption across functional areas such as Commercial, R&D, and Operations. You will co‑create business‑led AI roadmaps, size value opportunities, establish and run enterprise AI governance processes, and lead broad enablement processes so colleagues can confidently and safely use internal and external AI tools. You will collaborate closely with functional AI topic leads and the INDIGO program manager, while building an AI strategy team as the function matures. This role operates at the Director level and requires a blend of strategic acumen, governance expertise, AI knowledge, and strong communication that translates AI potential into measurable business impact. This role will work a weekly hybrid schedule in our Waltham office.
Essential Areas of Responsibility
AI Business Strategy & Portfolio Prioritization
Enterprise AI Governance
AI Education & Evangelism
Leadership
Basic Qualifications:
Minimum Education & Experience Requirements:
Technical Knowledge/Skills:
Competencies
Preferred Qualifications:
Personal Attributes:
Self‑starter who thrives in ambiguity; strong ownership and follow‑through
Skilled at business engagement and balancing evolving priorities; proactive communicator with excellent executive‑level writing and presentation skills
Demonstrated ability to multitask across departments and vendor partners; willingness to learn new tools and approaches
Commitment to a culture of inclusion and belonging. Ability to work 2–3 days/week in our Waltham office
The annual base salary for this position ranges from $220,000 to $250,000. In addition, this position is eligible for an annual performance pay bonus. Exact compensation may vary based on skills, training, knowledge, and experience. Alkermes offers a competitive benefits package. Additional details can be found on our careers website: www.alkermes.com/careers#working-here
#LI-TS1

At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.
Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions.
Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers and broader impacted communities. We remain committed to patient engagement, responsible and sustainable operations, and equitable access to quality treatment.
Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
See our Community Guidelines: https://www.alkermes.com/social-community-guidelines